The University of California, Los Angeles School of Medicine—known as the David Geffen School of Medicine at UCLA —is an accredited medical school located in Los Angeles, California, United States. The school was renamed in 2001 in honor of media mogul David Geffen who donated $200 million in unrestricted funds.

During the past decade, UCLA Medical Center / David Geffen School of Medicine conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "UCLA Medical Center / David Geffen School of Medicine" #1 collaborator was "Merck Sharp & Dohme LLC" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "UCLA Medical Center / David Geffen School of Medicine" are "Esophageal Adenocarcinoma" (1 trials), "Gastric Adenocarcinoma" (1 trials), "Gastroesophageal Junction Adenocarcinoma" (1 trials), "HER2 Mutations Breast Neoplasms" (1 trials) and "HER2 Positive Breast Cancer" (1 trials). Many other conditions were trialed in "UCLA Medical Center / David Geffen School of Medicine" in a lesser frequency.

Most popular intervention types in "UCLA Medical Center / David Geffen School of Medicine" are "Drug" (4 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Trastuzumab" (2 trials), "tucatinib" (2 trials), "Combination product: Trastuzumab + Pertuzumab" (1 trials), "Pertuzumab" (1 trials) and "Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "UCLA Medical Center / David Geffen School of Medicine" are 3 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "UCLA Medical Center / David Geffen School of Medicine". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in UCLA Medical Center / David Geffen School of Medicine, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in UCLA Medical Center / David Geffen School of Medicine, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".